VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacogenetics - Back to reality | Andrew Owen, BSS, MSC, PhD, FSBView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Looking Backwards: Hormonal Contraception and ARTv | Kimberly Scarsi, PharmD, MS, FCCPView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Janssen - Rilpivirine | Herta Crauwels, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Target Concentrations | Angela Kashuba, PharmDView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016The FDA Perspective on Hepatitis C Drug Resistance | Patrick Harrington, PHDView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhDView Video
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian KirbyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping FengView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de WetView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy EleyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer KingView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy KimView Slideset
